Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of the above product due to an error in one component of the autoinjector believed to cause some pens to fail to activate and deliver adrenaline. More information is provided in the attached alert.
It is important to note that while Emerade stock held by patients is not being recalled, patients and caregivers in possession of Emerade pens need to be informed of updated safety information about the risk of failure to activate.
Healthcare professionals (GP Practices, Pharmacies) should, where possible, contact patients and carers with Emerade pens, to inform them of the additional advice contained within this alert. Additionally, no further supplies of Emerade will be available on the UK market until the issue has been resolved, therefore patients and carers should be appropriately trained to use other brands.
Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts.